文献速递抗栓抗凝管理药物不良反应与药物警戒

利伐沙班治疗肿瘤相关静脉血栓的真实世界研究系统综述与荟萃分析

Systematic Review and Meta-Analysis of Real-World Studies Evaluating Rivaroxaban for Cancer-Associated Venous Thrombosis.
PubMed 文献 · Pharmacotherapy · 2018-05-10

系统评价真实世界研究,评估利伐沙班治疗肿瘤相关静脉血栓(CAT)患者中复发性VTE、大出血及全因死亡的发生率。纳入6项研究,汇总发生率分别为4.2%、2.9%和16.1%,提示复发性VTE和大出血发生率与近期随机试验相近,死亡率较低。

要点

  • 利伐沙班治疗CAT的复发性VTE汇总发生率为4.2%(95%CI 2.6-6.6%)。
  • 大出血汇总发生率为2.9%(95%CI 1.6-5.0%),与随机试验结果相近。
  • 全因死亡汇总发生率为16.1%(95%CI 6.0-36.6%),低于许多CAT抗凝试验。

核心结论

  • 利伐沙班治疗CAT患者的复发性VTE和大出血发生率与近期随机试验所见相似。
  • 汇总死亡率低于许多抗凝CAT试验报告的水平,可能提示利伐沙班用于癌症严重程度较低的患者。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE和SCOPUS至2017年9月,纳入≥20例患者的真实世界研究。
  • 共纳入6项研究,其中3项前瞻性、3项回顾性,样本量41至949例,随访时间164至496天。

主要发现

  • 复发性VTE加权平均发生率为4.2%(95%CI 2.6-6.6%;I2=31%)。
  • 大出血加权平均发生率为2.9%(95%CI 1.6-5.0%;I2=59%)。
  • 全因死亡加权平均发生率为16.1%(95%CI 6.0-36.6%;I2=96%)。
  • 研究中最常见的活动性癌症部位为胃肠道(范围12.0-56.0%)、泌尿生殖系统(8.6-26.0%)和乳腺(9.3-25.5%)。

临床怎么用

  • 真实世界数据显示利伐沙班用于CAT的复发性VTE和大出血风险与随机试验相近,可作为临床决策参考。
  • 死亡率较低可能反映接受利伐沙班的CAT患者癌症严重程度较低,选择患者时需考虑此因素。

局限性

  • 纳入研究数量较少(仅6项),且为真实世界研究,可能存在选择偏倚。
  • 全因死亡的异质性极高(I2=96%),汇总结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: While not designated as guideline-recommended first-line anticoagulation therapy, about one in five patients in the United States receive rivaroxaban for the treatment of cancer-associated venous thrombosis (CAT). METHODS: A systematic review and meta-analysis were performed to evaluate the incidences of recurrent venous thromboembolism (VTE), major bleeding, and all-cause mortality in rivaroxaban patients treated for CAT in routine practice. Literature searches of MEDLINE and SCOPUS were performed through September 2017 to identify real-world studies of ≥ 20 patients evaluating the incidence of recurrent VTE, major bleeding, or all-cause mortality in CAT patients anticoagulated with rivaroxaban. Using a Hartung-Knapp random-effects model, the pooled incidence estimates and 95% confidence intervals (CIs) were calculated for each end point. RESULTS: Six studies evaluating rivaroxaban for CAT were identified. Of these, three were prospective and three were retrospective. Study sample sizes ranged from 41 to 949 patients, and duration of follow-up ranged from 164 to 496 days. The most frequent active cancer sites reported in studies were gastrointestinal (range: 12.0-56.0%), genitourinary (range: 8.6-26.0%), and breast (range: 9.3-25.5%). The weighted average incidences of recurrent VTE, major bleeding, and all-cause mortality were 4.2% (95% CI = 2.6-6.6%; I2 = 31%), 2.9% (95% CI = 1.6-5.0%; I2 = 59%), and 16.1% (95% CI = 6.0-36.6%; I2 = 96%). CONCLUSIONS: This meta-analysis suggests that incidences of recurrent VTE and major bleeding among rivaroxaban-managed patients are not dissimilar to those seen in recent randomized trials of anticoagulation in CAT. The pooled incidence for mortality was lower than reported in many anticoagulation CAT trials. This may suggest that rivaroxaban is being used in CAT patients who have less severe cancer.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Martinez BK, Sheth J, Patel N, et al. Systematic Review and Meta-Analysis of Real-World Studies Evaluating Rivaroxaban for Cancer-Associated Venous Thrombosis. Pharmacotherapy. 2018. PMID: 29604102. doi:10.1002/phar.2113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。